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L actoferrin (Lf) is an 80-kDa iron-binding glyco-protein that is mainly found in exocrine secre-
tions,  such as breast milk [1 , 2],  and in the secondary 
granules of neutrophils [3].
The affinity of Lf for iron is far stronger than that of 
transferrin,  the closest relative of Lf in the transferrin 
family of proteins [4].  Thus,  Lf is considered an iron 
chelator rather than a transporter.  In regard to its func-
tion,  Lf was first postulated to act as an iron chelator to 
protect breast-fed infants from enteric pathogens that 
require iron [5].  In this context,  it is likely that Lf in the 
secondary granules of neutrophils sequesters toxic iron 
released from destroyed tissue and keep leukocytes safe 
at the site of inflammation.  Lf is also one of the compo-
nents of neutrophil extracellular traps (NETs),  which 
are a fibrous network of DNA released from the nuclei 
of neutrophils,  and appears to participate in the killing 
of bacteria trapped on NETs [6].
Apart from such roles in innate immunity,  Lf pos-
sesses multiple functions in the regulation of the 
immune system and acts as a transcription factor in the 
regulation of protein synthesis [7-9].  For example,  Lf 
enhances natural killer cell activity [10] and inhibits 
lipopolysaccharide-mediated production of interleu-
kin-1,  interleukin-6,  and tumor necrosis factor-alpha 
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Lactoferrin (Lf) is an iron-binding glycoprotein mainly found in exocrine secretions and the secondary granules 
of neutrophils.  In the central nervous system (CNS),  expression of the Lf protein has been reported in the 
lesions of some neurodegenerative disorders such as Alzheimer’s disease,  Parkinson’s disease,  and amyotrophic 
lateral sclerosis,  as well as in the aged brain.  Lf is primarily considered an iron chelator,  protecting cells from 
potentially toxic iron or iron-requiring microorganisms.  Other biological functions of Lf include immuno-
modulation and transcriptional regulation.  However,  the roles of Lf in the CNS have yet to be fully clarified.  In 
this study,  we raised an antiserum against mouse Lf and investigated the immunohistochemical localization of 
Lf-like immunoreactivity (Lf-LI) throughout the CNS of adult mice.  Lf-LI was found in some neuronal popula-
tions throughout the CNS.  Intense labeling was found in neurons in the olfactory systems,  hypothalamic 
nuclei,  entorhinal cortex,  and a variety of brainstem nuclei.  This study provides detailed information on the 
Lf-LI distribution in the CNS,  and the findings should promote further understanding of both the physiological 
and pathological significance of Lf in the CNS.
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[11 , 12].  Unlike other members of the transferrin fam-
ily,  Lf has a strongly basic region near its N-terminus,  
which binds specific DNA sequences [13],  and thus acts 
as a novel transcription factor.  Lf was found to down-
regulate granulocyte macrophage colony-stimulating 
factor promoter in interleukin-1 beta-stimulated fibro-
blasts [14].
In the CNS,  it has been reported that Lf is expressed 
in a variety of neurodegenerative conditions,  such as 
Alzheimer’s disease [15 , 16],  Parkinson’s disease [17],  
amyotrophic lateral sclerosis,  and Pick’s disease [15].  Lf 
has been immunohistochemically demonstrated to 
localize mainly in neurons affected by these neurode-
generative lesions.  The high binding affinity of Lf to 
ferric ions leads us to speculate that Lf may protect neu-
rons from oxygen free radicals by chelating potentially 
toxic iron in the brain.  However,  because of the many 
putative functions of Lf described above,  the role of Lf 
in the CNS is yet to be determined.
To clarify the physiological distribution of Lf in the 
CNS,  we raised an antiserum against a synthetic oligo-
peptide specific for mouse Lf and determined the 
immunohistochemical localization of lactoferrin-like 
immunoreactivity (Lf-LI) in the mouse CNS.  We show 
that Lf is found in a variety of neuronal populations 
throughout the CNS of ten-week-old mice.  This is the 
first report to describe the detailed distribution of Lf-LI 
in the healthy CNS.
Materials and Methods
All animal experiments were approved by the insti-
tutional Review Board of the Osaka Medical College 
(approval nos. 30113 and 2019-113) and were performed 
according to procedures outlined in the Guide for the 
Animal Care and Use of Laboratory Animals of the 
Osaka Medical College.
Production of an antiserum to mouse lactoferrin.
A synthetic oligopeptide specific for mouse Lf 
(RWQNEMRKVGGPPLSC) was prepared,  conjugated 
with bovine serum albumin (Peptide Institute Inc.,  
Osaka,  Japan) and then used in the immunization of 
rabbits to raise a polyclonal antibody against the syn-
thetic peptide.  This oligopeptide corresponds to amino 
acid residues 39-54 of mouse Lf,  which are in the first 
domain of the N-terminal lobe.  This amino acid 
sequence has no homology to mouse transferrin.  Based 
on the three-dimensional structure of human Lf,  this 
mouse sequence is surface-exposed and contains a tran-
sition from an alpha-helix to a beta-strand structure 
[18].
Western blot analysis. Male ICR mice (10 weeks 
of age) were used in this study.  The animals (n = 3) were 
euthanized with sodium pentobarbital (120 mg/kg,  i.p.) 
and then decapitated.  The whole brains were homoge-
nized in three volumes of ice-cold 20 mM Tris-HCl 
(pH 7.6) containing 150 mM NaCl,  1% NP-40,  0.1% 
CHAPS,  0.1% SDS and protease inhibitor cocktail 
(CompleteTM; Roche,  Basel,  Switzerland),  and incu-
bated on ice for 30 min.  The homogenate was centri-
fuged at 12,000 rpm for 30 min at 4°C.  The supernatant 
was removed and again centrifuged at 12,000 rpm for 
30 min at 4°C.  The supernatant collected as total cell 
lysate was used for western blot analysis.
Ten-µg protein samples were electrophoresed on 
10% sodium dodecyl sulfate-polyacrylamide gel (SDS-
PAGE) and transferred to a nitrocellulose membrane 
(HybondTM-ECL; Amersham,  Buckinghamshire,  UK).  
Equivalent protein loading was confirmed by staining 
the membrane with 0.1% Ponceau S in 5% acetate.  The 
membrane was blocked with 3% bovine serum albumin 
(fraction V; Sigma) in 20 mM Tris-HCl (pH 7.6) con-
taining 150 mM NaCl and 0.1% Tween 20 (TBS-T) for 
1 h at room temperature (RT) and further incubated 
overnight with anti-Lf antiserum (1 : 100,000) in TBS-T 
at 4°C.  As a negative control experiment,  anti-Lf anti-
serum was replaced with pre-immune serum 
(1 : 100,000) or the antiserum that had been adsorbed 
overnight at 4°C with 10 mM of the synthetic Lf oligo-
peptide.  The membrane was washed with TBS-T,  
reacted with HRP-linked anti-rabbit immunoglobulin 
(1 : 5,000; Amersham) in TBS-T,  and washed again 
with PBS-T.  Immunoreactive bands were visualized by 
enhanced chemiluminescence (ECL,  Amersham).
Tissue preparation for immunohistochemistry.
The animals (n = 3) were euthanized with sodium pen-
tobarbital (120 mg/kg,  i.p.) and perfused transcardially 
with 10 mM phosphate-buffered saline (pH 7.2) fol-
lowed by a fixative containing 4% paraformaldehyde 
(PFA),  0.35% glutaraldehyde,  and 0.2% picric acid in 
100 mM phosphate buffer (pH 7.4).  The brains and 
spinal cords were removed and post-fixed for approxi-
mately 24 h in the same fixative excluding glutaralde-
hyde,  cryoprotected in 15% sucrose in 100 mM phos-
phate buffer for 48 h,  snap frozen with powdered dry 
ice,  and cut coronally on a cryostat at 20 µm.  Sections 
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were stored in 100 mM phosphate-buffered saline con-
taining 0.3% triton X-100 (PBS-T,  pH 7.4) and sub-
jected to immunohistochemical staining using the 
free-floating method [19 , 20].  The above procedures 
were carried out at 4°C.
Immunohistochemistry. Free-floating sections at 
each 100-µm interval throughout the rostral-caudal axis 
of the brain and spinal cord were immunolabelled for Lf.  
Endogenous peroxidase activity in the sections was 
quenched with 0.5% H2O2 in PBS-T for 30 min.  The 
sections were first incubated for 10 days with anti-Lf 
serum (1 : 100,000),  for 24 h with biotinylated anti- 
rabbit IgG (diluted 1 : 1,000; Vector Laboratories,  
Burlingame,  CA,  USA),  and for 1 h with the avidin- 
biotin peroxidase complex (diluted 1 : 2,000; Vector 
Laboratories).  All antibody dilutions and washing of 
sections were performed with PBS-T.  Peroxidation 
activity was visualized with 0.02% 3, 3’-diaminobenzi-
dine (DAB; Katayama Chemical,  Osaka,  Japan),  
0.0045% H2O2,  and 0.3% nickel ammonium sulphate in 
50 mM Tris-HCl buffer (pH 7.6).  The stained sections 
were mounted on glass slides coated with silane (APS-
01; Matsunami Glass Industry,  Kishiwada,  Japan),  
air-dried,  dehydrated,  and cover slipped.  Images were 
digitally recorded with a DS-Ri1 camera (Nikon,  Tokyo) 
on a Nikon Eclipse 80i light microscope (Nikon).
For immunohistochemical controls,  primary antise-
rum was replaced with pre-immune rabbit serum at the 
same dilution (1 : 100,000).  In addition,  anti-Lf antise-
rum that had been previously adsorbed with 10 mM of 
the synthetic antigen peptide for 24 h at 4°C was used as 
the control antiserum.  As a positive control,  10-µm 
cryosections mounted on the glass slides were prepared 
from the uteri of perfusion-fixed mice (10 weeks old;  
n = 2).  Briefly,  the slides were incubated for 30 min 
with 1% H2O2 in PBS-T,  for 30 min with 5% normal 
goat serum in PBS-T,  overnight at 4°C with anti-Lf 
antiserum (1 : 5,000) or pre-immune serum (1 : 5,000),  
for 1 h with biotinylated goat anti-rabbit IgG (diluted 
1 : 100; Vector Laboratories),  and for 30 min with the 
avidin-biotin peroxidase complex (diluted 1 : 200;  
Vector Laboratories).  The immunoreactivities were 
visualized by incubating the slides with DAB plus nickel 
ammonium sulphate as described above.  We photo-
graphed these control slides using a Keyence BZ-X700 
microscope equipped with phase contrast objective 
lenses (Keyence,  Osaka,  Japan) to outline negatively 
stained sections.
Results
Specificity of antiserum against Lf. The poly-
clonal antiserum was tested for specificity using western 
blotting of mouse brain homogenates.  This antiserum 
detected a single band with an estimated molecular 
weight of approximately 80 kDa (Fig.1A, lane 1). Controls 
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Fig. 1　 The specificity of anti-lactoferrin serum.  
A,  Western blot analysis of mouse brain homog-
enate.  Equivalent protein loading was confirmed 
by staining the membrane with 0.1% Ponceau S 
in 5% acetate.  The antiserum (diluted 
1 : 100,000) detected a single band at 80  kDa (A,  
lane 1).  Controls using either pre-immune serum 
(A,  lane 2) or antiserum previously adsorbed with 
10 mM of the synthetic peptide antigen 
(RWQNEMRKVGGPPLSC) used for immuniza-
tion (A,  lane 3) did not reveal any bands.  
Molecular sizes are indicated at left (in 
kDa); B ,C,  Photomicrographs of positive control 
immunolabeling of the mouse endometrial glands 
with the anti-lactoferrin antiserum (B) and with 
pre-immune serum (C); D-F,  Immunolabeling of 
the brain with anti-lactoferrin antiserum (D) and 
negative control staining with pre-immune serum 
(E) and the pre-adsorbed antiserum described 
above (F).  Phase contrast images are shown in 
panels B-F.  Scale bars=100 µm.
using either pre-immune serum (Fig. 1A,  lane 2) or 
antiserum previously adsorbed with 10 mM of the syn-
thetic peptide antigen (RWQNEMRKVGGPPLSC) used 
for immunization (Fig. 1A,  lane 3) did not show any 
bands.
Immunohistochemical staining of the mouse uterus 
with the antiserum revealed Lf-LI in the epithelium of 
the endometrial glands (Fig. 1B),  whereas the pre-im-
mune serum did not yield such immunoreactivity 
(Fig. 1C).  Lf-LI was similarly observed in the mouse 
CNS (Fig. 1D).  Substituting the antiserum with the 
pre-immune serum or pre-adsorbed anti-serum com-
pletely abolished Lf-LI (Fig. 1E , F).
Distribution of Lf-like immunoreactivity in the 
mouse brain and spinal cord. Lf-LI was observed in 
a certain population of neurons throughout the ros-
tral-caudal extent of the brain and spinal cord.  The 
reaction product in neurons appeared to occur on the 
surface of cells and in the cytoplasm.  In some brain 
regions,  dendritic or axonal processes were also visible.  
Maps of positive neuronal somata are presented in Fig. 2 
with 18 schematic drawings of coronal sections,  corre-
sponding to the atlas of the mouse brain by Hof et al.  
[21],  and in Fig. 10A with a schematic drawing of the 
cervical spinal cord.
Telencephalon. In the main olfactory bulb,  Lf-LI 
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Fig. 2　 Mapping of neuronal lactofer-
rin-like immunoreactivity in coronal sections 
of the mouse brain.  Lactoferrin-like immu-
noreactivity is depicted by dots that repre-
sent both the number and distribution of 
labeled cells.  For the intensity of signals,  
see Table 1.  Small dots=1-5 labeled 
cells ; medium dots=6-10 labeled 
cells; large dots=approximately 50 labeled 
cells.  The number indicates the anteropos-
terior distance of the panel from the 
bregma.
was found in both the cytoplasm and dendrites of mitral 
cells,  tufted cells,  and periglomerular cells (Fig. 2A and 
3A , B).  Lf-LI in dendrites was prominent in the exter-
nal plexiform layer and to a lesser degree in the glomer-
uli (Fig. 3A , B).  In the accessory olfactory bulb,  scat-
tered neurons in the mitral cell layer were clearly 
positive for Lf-LI (Fig. 3A , C , D),  and the external 
plexiform layer and glomerular layer showed diffuse and 
fibrous staining (Fig. 1A , D).  Many positive neurons 
were seen in the anterior olfactory nuclei and tenia tecta 
(Fig. 2B-D and 3E).
The lateral stripe of the striatum contained weakly 
immunoreactive but concentrated small-sized neurons 
(Fig. 2F-H and 4A).  The piriform cortex contained pos-
itive neurons of various sizes according to its layer 
structure (Fig. 2D-K and 4A).  Moderate staining was 
seen in the tightly packed small pyramidal cells in layer 
II,  and relatively dense staining was seen in the 
medium to large-sized pyramidal cells scattered in lay-
ers III-IV.  Other paleocortices,  including the agranular 
insular cortex (Fig. 2E-H,  4B),  lateral entorhinal cortex 
(Fig. 2J-N and 4C),  and perirhinal cortex (Fig. 2L , M 
and 4D),  had a number of medium-sized neurons 
showing neuronal somata and proximal axons and den-
drites positive for Lf-LI.  No positive structures were 
seen in the hippocampal formation except for occa-
sional horizontal cells in the stratum oriens in the CA1 
(Fig. 4E) and other areas (Fig. 2I-M).  Unlike the paleo-
cortex,  the neocortex contained only a few positive 
non-pyramidal cells scattered throughout the layer 
structure (Fig. 2F-N and 4F).  Among the neocortices,  
the primary and secondary motor cortex were the only 
exception,  where a number of moderately positive neu-
rons were observed (Fig. 2B-E).  Lf-LI was not found in 
the caudoputamen (Fig. 2E-J).
Many,  but not all,  neurons in the nuclei of the hor-
izontal- and vertical-limb of the diagonal band showed 
intense Lf-LI (Fig. 2F and 5A).  Lf-positive neurons were 
packed in the supraoptic nucleus (Fig. 2H and 5B).  The 
medial preoptic area,  including the medial,  lateral,  and 
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Fig. 3　 Lactoferrin-like immunoreactivity in the mouse olfactory system.  Results are 
shown for the main olfactory bulb (A ,B),  accessory olfactory bulb (A ,C,  and D),  and 
anterior olfactory nuclei and tenia tecta (E).  AOM,  anterior olfactory nucleus,  medial 
part; AOV,  anterior olfactory nucleus,  ventral part; DEn,  dorsal endopiriform nucle-
us; DTT,  dorsal tenia tecta; EPl,  external plexiform layer of the olfactory bulb; E-
PlA,  external plexiform layer of the accessory olfactory bulb; Gl,  glomerular layer of 
the olfactory bulb; GlA,  glomerular layer of the accessory olfactory bulb; Mi,  mitral 
cell layer of the accessory olfactory bulb; MiA,  mitral cell layer of the accessory 
olfactory bulb.  Scale bars=20 µm for (A ,D); 5 µm for (B ,C) and 50 µm for (E).
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Fig. 4　 Neuronal lactoferrin-like immunore-
activity in the piriform cortex and lateral stripe 
of the striatum (A),  posterior part of the agran-
ular insular cortex (B),  lateral entorhinal cortex 
(C),  perirhinal cortex (D),  stratum oriens of 
the hippocampal CA1 area (E),  and layer I of 
the frontal cortex (F).  LSS,  lateral stripe of the 
striatum; Pir,  piriform cortex.  Scale 
bars=20 µm for (A) and 5 µm for (B-F).
Fig. 5　 Lactoferrin-like immunoreactivity in 
the telencephalon.  Results are shown for 
nuclei of the horizontal- and vertical-limb of the 
diagonal band (A),  the supraoptic nucleus 
(B),  the medial preoptic nucleus (C),  and the 
amygdalohippocampal area,  cortical amygda-
loid nucleus,  and amygdalopiriform transition 
area (D).  AHi,  amygdalohippocampal area;  
APir,  amygdalopiriform transition area; Co,  
cortical amygdaloid nucleus; HDB,  nucleus of 
the horizontal limb of the diagonal band; SO,  
supra optic nucleus; VDB,  nucleus of the 
vertical limb of the diagonal band.  Scale 
bars=20 µm for (A, C, D) and 10 µm for (B).
central part of the medial preoptic nuclei,  was abun-
dant in medium-sized positive neurons with moderate 
to strong staining intensity (Fig. 2G , H and 5C).  A 
number of neurons stained with moderate to strong 
intensity were found in the amygdalohippocampal area,  
cortical amygdaloid nucleus,  and amygdalopiriform 
transition area (Fig. 2I-M and 5D).
Diencephalon. Lf-LI was most prominent in a 
series of hypothalamic nuclei in the CNS.  Medium-
sized positive neurons were concentrated in the anterior 
parvicellular part of the paraventricular hypothalamic 
nucleus,  and some larger neurons with intense staining 
were scattered around the nucleus (Fig. 2H , I and 6A).  
The dorsomedial hypothalamic nucleus contained mul-
tipolar neurons with intensely stained neuronal somata 
and dendrites,  while in the ventromedial hypothalamic 
nucleus,  positive neurons were more frequent but had 
less staining intensity (Fig. 2J and 6B).  The medial part 
of the arcuate nucleus comprised small-sized positive 
neurons and Lf-LI was confined to the neuronal somata 
and proximal processes (Fig. 2I-K and 6C).  The lateral 
hypothalamic area showed large-sized positive neurons 
with strong intensity (Fig. 2I-K and 6D).  Medium-sized 
positive neurons were diffusely scattered in the poste-
rior hypothalamic area (Fig. 6E).  Among thalamic 
structures,  only the intergeniculate leaf had a concen-
trated population of positive neurons (Fig. 2K , L;  
photographs not shown).
Mesencephalon. Significant Lf-LI was not pres-
ent in the substantia nigra,  and positive neurons were 
found medial and dorsal to the substantia nigra pars 
compacta (Fig. 2L , M and 7A).  Although the neuronal 
somata in the superior colliculus showed only faint pos-
itive staining,  Lf-LI was found in the fibrous network in 
the zonal layer,  superficial gray,  and optic nerve layer 
(Fig. 7B).  In the periaqueductal gray,  positive neurons 
were scattered and somewhat dense in the lateral peri-
aqueductal gray (Fig. 2M , N and 7C).  The Edinger-
Westphal nucleus had strong Lf-LI in the large-sized 
neurons (Fig. 2M and 7C).  Large-sized neurons in the 
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Fig. 6　 Lactoferrin-like immunoreactivity in the hypothalamic areas.  Results are 
shown for the anterior parvicellular part of the paraventricular hypothalamic nucleus 
(A),  dorsomedial hypothalamic nucleus and ventromedial hypothalamic nucleus (B),  
medial part of the arcuate hypothalamic nucleus and ventromedial nucleus (C),  lateral 
hypothalamic area (D),  and posterior hypothalamic area (E).  ArcM,  arcuate hypotha-
lamic nucleus,  medial part; DM,  dorsomedial hypothalamic nucleus; VMH,  ventro-
medial hypothalamic nucleus.  Scale bars=20 µm for (A ,D ,E) and 10 µm for (B ,C).
oculomotor nucleus showed light Lf-LI (Fig. 7C).  In the 
dorsal raphe nuclei,  medium-sized neurons with a 
mostly bipolar morphology showed moderate to strong 
Lf-LI in the dorsal (Fig. 7D),  ventral,  and ventromedial 
regions (Fig. 2N).  Moderate to strong Lf-LI was found 
extensively but not densely in the supramammillary 
nucleus (Fig.2K,L and 7E).  The nucleus of the brachium 
inferior colliculus contained occasional neurons with 
intense Lf-LI (Fig. 2N and 7F).  Moderately positive 
neurons with small round or bipolar morphology were 
seen in the paralemniscal nucleus (Fig. 2N and 7G).
Pons and medulla. Lf-LI was present in a moder-
ate population of cells in the superior vestibular nucleus 
and genu of the facial nerve (Fig. 2P and 8A).  The facial 
nucleus (Fig. 2P and 8B),  lateral superior olive,  and 
superior paraolivary nucleus (Fig. 2O and 8C) contained 
moderately positive neurons.  The lateral paragiganto-
cellular nucleus (Fig. 2P, Q and 8B),  gigantocellular 
reticular nucleus (Fig. 2P, Q and 8D),  and gigantocellu-
lar reticular nucleus,  alpha part (Fig. 2P and 8E) 
showed moderate to strong Lf-LI in large-sized multi-
polar neurons.  Positive neurons in the ambiguus 
nucleus were tightly packed (Fig. 2Q and 8F).  In the 
mesencephalic trigeminal nucleus,  positive neurons 
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Fig. 7　 Lactoferrin-like immunoreactivity in the mesencephalon.  Results are shown 
for the ventral tegmental area (A),  superior colliculus (B),  Edinger-Westphal nucleus,  
lateral periaqueductal gray and oculomotor nucleus (C),  dorsal part of the dorsal raphe 
nucleus (D),  supramammillary nucleus (E),  nucleus of the brachium inferior colliculus 
(F),  and paralemniscal nucleus (G).  III,  oculomotor nucleus; EW,  Edinger-Westphal 
nucleus; LPAG,  lateral periaqueductal gray.  Scale bars=20 µm for (A ,C ,E) and 
10 µm for (B ,D ,F ,G).
had large and round morphology,  and axons were also 
positive (Fig. 2O and 9A , B).  Large-sized neurons with 
bipolar or multipolar morphology in the motor trigem-
inal nucleus were positive for Lf-LI together with their 
nerve fibers (Fig. 2O and 9A , C).  There were scattered 
positive neurons in the central gray (Fig. 2O and 9A).  
Medium-sized positive neurons were found in the soli-
tary tract nucleus including the intermediate,  medial,  
ventral,  and ventrolateral regions (Fig. 2Q, R and 9D).  
The dorsal motor nucleus of the vagus and hypoglossal 
nucleus showed light to moderate Lf-LI (Fig. 2Q and 
9D).  In the lateral reticular nucleus,  most neurons 
showed weak to moderate Lf-LI with occasional strongly 
immunoreactive cells (Fig. 2R and 9E).  The parvicellu-
lar reticular nucleus contained scattered positive neu-
rons,  but most of them showed strong Lf-LI (Fig. 2Q 
and 9F).  Small-sized neurons in the rostroventrolateral 
reticular nucleus showed Lf-LI of variable intensity 
(Fig. 2Q, R and 9G).
Cerebellum. Clear Lf-LI was observed in the 
cytoplasm and proximal dendrites of the Purkinje cells 
(Fig. 2O-R and 9H).
Spinal cord. In the spinal cord,  sporadic Lf-LI 
was seen in neurons in any layers of the gray matter 
(Fig. 10A-C).  However,  a number of large-sized motor 
neurons were conspicuous in layer IX with moderate 
immunoreactivity (Fig. 10D).
Discussion
The antiserum against a synthetic oligopeptide from 
mouse Lf detected a specific 80-kDa protein in mouse 
brain extract (Fig. 1A) and showed its immunoreactivity 
mainly in the somata of various neuronal populations 
throughout the rostrocaudal axis of the mouse CNS 
(Table 1 and Fig. 2).  To our knowledge,  this is the first 
report to describe the detailed distribution of Lf-LI in 
the normal CNS using a specific antiserum to mouse Lf.
Kawamata et al.  [16] and Leveugle et al.  [15] 
observed pathologic Lf-immunolabeling in neurofibril-
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Fig. 8　 Lactoferrin-like immunoreactivity in 
the pons.  Results are shown for the genu of 
the facial nerve (A),  facial nucleus and lateral 
paragigantocellular nucleus (B),  lateral supe-
rior olive and superior paraolivary nucleus (C),  
gigantocellular reticular nucleus (D),  alpha 
part of the gigantocellular reticular nucleus 
(E),  and ambiguus nucleus (F).  VII,  facial 
nucleus; LSO,  lateral superior olive; LPGi,  
lateral paragigantocellular nucleus; SPO,  
superior paraolivary nucleus.  Scale bars=  
10 µm for (A ,D ,F); 20 µm for (B ,C) and 5 µm 
for (E).
lary tangles and senile plaques in the brains of patients 
with Alzheimer’s disease,  but reported that the brains of 
young control subjects were devoid of Lf staining,  while 
the brains of elderly control subjects showed Lf labeling 
in some large pyramidal neurons in the prefrontal cor-
tex [15] or in neurons in several areas,  including the 
angular gyrus,  hippocampus and entorhinal cortex [16].  
It appears that neurons accumulate more Lf in particu-
lar brain areas with aging.  Using our newly developed 
antibody,  it will be possible to perform detailed investi-
gations of chronological changes in Lf localization both 
in the developing and aging mouse brain.  Lf labeling 
was also found in glial cells in the elderly brain [16],  
and in microglia in the prefrontal subcortical white 
matter of a patient with Alzheimer’s disease [15].  In our 
study,  glial staining for Lf was not found.  Localization 
of Lf to glial cells may also be associated with aging via 
pathologic events such as inflammation,  or simply 
associated with a species difference.
It is noteworthy that Lf-LI was scarce or weak in the 
majority of neocortices,  and in the hippocampus,  stri-
atum,  and substantia nigra,  which are sites commonly 
affected by some neurodegenerative diseases and/or 
sites vulnerable to ischemia [22].  The significance of 
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Fig. 9　 Lactoferrin-like immunoreactivity in 
the medulla and cerebellum.  Results are 
shown for the motor trigeminal nucleus,  mes-
encephalic trigeminal nucleus,  and central 
gray (A),  mesencephalic trigeminal nucleus 
(B),  motor trigeminal nucleus (C),  nucleus of 
the solitary tract and hypoglossal nucleus (D),  
lateral reticular nucleus (E),  parvicellular retic-
ular nucleus (F),  rostroventrolateral reticular 
nucleus (G),  and Purkinje cells in the cerebel-
lar cortex (H).  X,  dorsal motor nucleus of 
vagus; XII,  hypoglossal nucleus; cc,  central 
canal; CG,  central (periaqueductal) gray; Gi,  
gigantocellular reticular nucleus; LRt,  lateral 
reticular nucleus; Me5,  mesencephalic tri-
geminal nucleus; Mo5,  motor trigeminal 
nucleus; PCRt,  parvicellular reticular nucle-
us; Pj,  Purkinje cell layer of the cerebellum;  
Sol,  solitary tract nucleus.  Scale bars=50 µm 
for (A); 10 µm for (B ,C ,E ,G) 20 µm for 
(D ,F),  and 5 µm for (H).
such a lack of Lf is unclear at present.  Since Lf has the 
potential to inhibit the formation of hydroxyl-radicals 
from superoxide and hydrogen peroxide by sequester-
ing free iron [23],  this observation allows us to specu-
late that Lf may confer protection against neuronal 
death by reducing oxidative stress,  which is considered 
one of the potential causes of neuronal cell death in 
neurodegenerative diseases and cerebrovascular dis-
eases.  If that is the case,  Lf could be of great therapeu-
tic value,  since orally administered Lf has been shown 
to improve neurocognitive function [24] and CNS 
inflammation [25] in animal models.
In this study,  the most intense Lf-LI was found in a 
series of hypothalamic nuclei (Table 1,  Fig. 6A-E).  
Indeed,  preferential expression of the Lf receptor in the 
hypothalamus [26] may support the idea that Lf is 
involved in physiological functions in the hypothala-
mus.  For instance,  some hormonal feedback to the 
hypothalamus could be provided by Lf transported 
from the periphery.  Indeed,  an imperfect estrogen 
response element is present in the 5’ flanking region of 
the Lf gene [27]; moreover,  Lf gene expression is 
highly sensitive to estrogen in the mouse uterus,  with 
the level of uterine Lf mRNA increasing up to 300-fold 
after estrogen administration [28].  In addition,  estro-
gen replacement therapy has potentially beneficial 
effects on cognitive and mnemonic functions in patients 
with Alzheimer’s disease [29 , 30].  Thus,  it is worth 
investigating whether any of those functions of estrogen 
are related to Lf accumulation in the CNS.
Although many different functions of Lf have been 
postulated (e.g.,  iron chelator,  immune modulator,  
transcription factor,  antimicrobial property,  and anti-
cancer property [7 , 8 , 31]),  the significance of the 
increased accumulation of Lf with age and in neurode-
generative disorders is not clear.  In fact,  it is not even 
known whether Lf is beneficial or detrimental in such 
disorders.  A recent report,  however,  has shown that 
parkin controls iron homeostasis in cells through ubiq-
uitylation of Lf,  which might explain how dysfunction 
of parkin leads to Parkinson’s disease [32].  Another in 
vitro study has suggested that Lf protects dopaminergic 
neurons by interacting with mitochondrial calcium 
homeostasis [33].
Receptors for Lf have been identified in different 
types of cells,  including lymphocytes [34],  platelets 
[35],  small intestine cells [36],  and epithelial cell lines 
from breast neoplasms [37].  As for the CNS,  the pres-
ence of the Lf receptor in the blood brain barrier 
[38 , 39] raises a question as to whether Lf is synthesized 
in neurons and/or transported from the plasma [40].  
Fillebeen et al.  [41 , 42] showed the presence of Lf 
mRNA in the mouse brain using sensitive PCR,  but 
failed to demonstrate its cellular localization using in 
situ hybridization,  suggesting that the level of Lf mRNA 
is very low or that such sensitive PCR analysis might 
have detected the Lf mRNA of blood origin (e.g.,  circu-
lating neutrophils).  Indeed,  we found that Lf mRNA 
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Fig. 10　 Lactoferrin-like immunoreactivity in 
the spinal cord.  Dots in the schematic drawing 
represent the mapping of the immunoreactivity in 
cervical spinal cord as comparable to Figure 2 
(small dots=1-5 labeled cells; medium dots=6-
10 labeled cells) (A).  Photomicrographs of the 
immunolabeled cervical spinal cord: an entire 
cross-section view (B),  layer X (C),  and layer IX 
(D).  cc,  central canal.  Scale bars=50 µm for 
(B); 20 µm for (C) and 5 µm for (D).
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　External plexiform layer (fibrous) +
　Mitral cell layer +
　Lateral olfactory tract +
　Dorsal lateral olfactory tract +
Accessory olfactory bulb
　External plexiform layer (fibrous) +
　Mitral cell layer +




Islands of Calleja +
Piriform cortex ++
Dorsal endopiriform nucleus ++
Ventral endopiriform nucleus +
Nucleus of the diagonal band (horizontal & vertical limb) ++
Medial preoptic area and nuclei (central,  medial & lateral) ++
Primary motor cortex +
Secondary motor cortex +
Cingulate cortex,  area 1 +
Prelimbic cortex +
Granular insular cortex +
Dorsal peduncular cortex +
Agranular insular cortex +
Entorhinal cortex +
Lateral entorhinal cortex +
Retrosplenial agranular cortex +
Basal ganglia
　Lateral stripe of the striatum +
　Ventral pallidum +
　Amygdala
　　Medial nuclei (anterodorsal,  anteroventral,  posterodorsal,  & posteroventral part) +
　　Anterior cortical nucleus +
　　Posterolateral cortical nucleus +
　　Posteromedial cortical nucleus +
　　Basomedial nuclei (anterior & posterior part) +
　　Basolateral nuclei (anterior & ventral part) +
　Bed nucleus of the accessory olfactory tract +
　Premammillary nuclei (dorsal and ventral part) ++
　Amygdalohippocampal area (anterolateral & posteromedial part) +




　Paraventricular nuclei (dorsal cap,  & anterior parvicellular,  medial parvicellular,  lateral magnocellular,  posterior & ventral part) ++++
　Periventricular nucleus +
　Ventromedial nuclei (anterior,  central,  dorsomedial & ventrolateral part) +++
　Arcuate nuclei ++




　Magnocellular nucleus of the lateral hypothalamus +++
　Dorsomedial nuclei (dorsal,  ventral & compact part) ++
　Medial tuberal nucleus ++
　Supramammillary nucleus ++











　Rostral interstitial nucleus of medial longitudinal fasciculus +
　Olivary pretectal nucleus +
　Ethmoid nucleus +
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Mesencephalon
Superior colliculus (zonal,  superficial gray & optic nerve layer) ++
Inferior colliculus
　Nucleus of the brachium ++
Medial geniculate nuclei (dorsal,  medial & ventral part) +
Tegmental nuclei
　Substantia nigra (lateral part) ++
　Edinger-Westphal nucleus ++
　Rostral linear nucleus of the raphe ++




　Dorsal raphe nuclei (dorsal,  ventral & ventrolateral part) +++
　Median raphe nucleus +
　Paratrochlear nucleus +
　Paralemniscal nucleus +
　Lateral periaqueductal gray ++
　Raphe magnus nucleus +
　Raphe pallidus nucleus +
　Medial parabrachial nucleus ++
　Mesencephalic trigeminal nucleus +
　Laterodorsal tegmental nucleus +





　　Central gray of the pons +
　　Central gray,  alpha part +
　　Pontine reticular nucleus (oral and caudal part) +
　　Rostroventrolateral reticular nucleus +
　　Caudoventrolateral reticular nucleus +
　　Gigantocellular reticular nucleus +
　　Lateral paragigantocellular nucleus +++
　　Dorsal paragigantocellular nucleus ++
　　Genu of the facial nerve ++
　　Accessory facial nucleus +
　　Prepositus nucleus +
　　Subcoeruleus nucleus,  alpha part +
　　Lateral reticular nucleus +
　　Medullary reticular nucleus (dorsal & ventral part) +
　　Nucleus of the solitary tract +
　Superior olivary complex
　　Superior paraolivary nucleus ++
　　Nucleus of the trapezoid body ++
　Cranial motor nuclei
　　Motor trigeminal nucleus (dorsolateral & ventromedial part) +++
　　Facial nucleus ++




　　Spinal trigeminal nucleus (oral & caudal part) [fibrous] +
　　Spinal trigeminal tract [fibrous] +
　Cochlear nuclei
　　Ventral cochlear nucleus +
　Vestibular nucleus
　　Lateral vestibular nucleus ++
　　Medial vestibular nucleus ++






　　Lateral cerebellar nucleus +




Relative intensities of Lf-LI were estimated by visual comparison of immunolabeled slides: ±,  faint; +,  low; ++,  moderate; +++,  strong; ++++,  very strong.
was undetectable by quantitative reverse transcription 
PCR in the mouse brain following transcardial perfu-
sion with PBS (unpublished data).  Yet,  we observed 
varied levels of Lf mRNA expression in somatic organs 
in the same mice,  with the highest levels in bone mar-
row.  Therefore,  we speculate that the neuronal Lf 
observed in this study was exogenously transported 
from the blood across the blood brain barrier.  In the 
future,  it would be helpful to examine in detail whether 
Lf is synthesized in the healthy CNS of young-adult 
mice.
The lack of an anti-mouse Lf antibody that is appli-
cable to immunohistochemistry appears to have ham-
pered studies on the role of Lf in various animal models 
of CNS disorders.  This study provided such an anti-
body,  and used it to reveal basic information on Lf 
distribution in the mouse CNS.  The availability of a 
suitable anti-mouse Lf antibody is expected to encour-
age extensive studies on the roles of Lf in the healthy,  
aging,  and neurodegenerating CNS.
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